Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Urothelial carcinoma in situ with "early papillary formation" vs "lateral spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial carcinoma: A survey of pathologist and urologist interpretations.

American journal of clinical pathology·2024

Same author

The Recent Advances in Molecular Diagnosis of Soft Tissue Tumors.

International journal of molecular sciences·2023

Same author

Polypoid Gastric Adenomyoma: A Rare Cause of Bleeding Treated With Polypectomy.

ACG case reports journal·2022

Same author

Enhanced Succinate Oxidation with Mitochondrial Complex II Reactive Oxygen Species Generation in Human Prostate Cancer.

International journal of molecular sciences·2022

Same author

Case of recurrent superficial CD34-positive fibroblastic tumor.

Journal of cutaneous pathology·2022

Same author

Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.

Biomedicines·2022

Same journal

Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients.

Sarcoma·2024

Same journal

Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States.

Sarcoma·2024

Same journal

Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients.

Sarcoma·2024

Same journal

ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.

Sarcoma·2024

Same journal

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.

Sarcoma·2024

Same journal

Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone.

Sarcoma·2024

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Chondrosarcoma: with updates on molecular genetics.

Mi-Jung Kim¹, Kyung-Ja Cho, Alberto G Ayala

¹Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea.

|March 16, 2011

Summary

This summary is machine-generated.

Chondrosarcoma (CHS) diagnosis requires correlating radiological and clinicopathological features due to morphologic challenges. Histologic grading, crucial for prognosis, is subjective; this study presents a grading system and updated genetic findings for CHS.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Related Experiment Videos

Last Updated: Jun 3, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Area of Science:

Orthopedic Oncology
Skeletal Radiology
Cancer Genetics

Background:

Chondrosarcoma (CHS) is a malignant cartilage tumor typically found in long and pelvic bones.
Accurate diagnosis of CHS can be challenging based on morphology alone, necessitating integrated clinicopathological and radiological assessment.
Prognosis is linked to histologic grading, but this method suffers from inter-observer variability.

Purpose of the Study:

To present a histologic grading system for conventional chondrosarcoma (CHS).
To detail clinicopathological and radiological findings of conventional CHS.
To review updated cytogenetic and molecular genetic findings in CHS biology.

Main Methods:

Correlation of radiological and clinicopathological features for CHS diagnosis.
Histologic grading system development and application.
Review of current cytogenetic and molecular genetic data for CHS subtypes (dedifferentiated, mesenchymal, clear cell).

Main Results:

A histologic grading system for conventional CHS is presented.
Clinicopathological and radiological characteristics of conventional CHS are detailed.
Updated cytogenetic and molecular genetic findings provide insights into CHS biology.

Conclusions:

The integration of radiological and clinicopathological data is essential for accurate CHS diagnosis.
A standardized histologic grading system can improve CHS prognosis assessment.
Emerging genetic markers hold promise for future therapeutic and prognostic strategies in chondrosarcoma.